Background: Cognitive impairment in drug-dependent patients under methadone maintenance treatment has been reported before. We assessed whether patients under buprenorphine, a partial mopioid agonist, perform better in cognitive tests measuring psychomotor performance as described in previous nonrandomized studies. Methods: We performed a randomized clinical trial in 62 drugdependent patients under either buprenorphine or methadone treatment. Sixteen patients dropped out of maintenance therapy, before the testing was performed, after 8 to 10 weeks of treatment. Several subtests of the Act & React Test System test battery were used measuring visual perception, selective attention, vigilance, reactivity, and stress tolerance. Findings: Although there were no differences in cognitive function at baseline, patients under buprenorphine treatment showed partially better results in some of the domains tested. The used tests are relevant when assessing driving ability. There was a significant correlation between dose of buprenorphine and some test results. We also found a correlation between age and reaction time and between duration of opioid dependence and results in some subtests. Interpretations (Conclusions): When comparing both treatments in drug dependent patients, buprenorphine produces partially less impairment on cognitive functions in some of the subtests of the psychomotor battery than methadone. This difference is specially relevant when it comes to driving ability and social functioning.
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B
uprenorphine is a partial m-opioid agonist which has been introduced into clinical practice as an alternative to methadone for treatment of drug dependence. Several studies have shown encouraging clinical results. 1 -6 Davids and Gastpar 7 concluded that buprenorphine is effective, well tolerated and, due to its pharmacological profile, a very safe drug. 8 Its unique profile includes a ceiling on agonist activity that decreases toxicity and risk for overdose. Its slow dissociation from the m-opioid receptor results in long duration of action which offers the possibility of alternate-day dosing schedules. Another potential benefit of buprenorphine treatment is that it may cause less impairment of psychomotor performance and driving ability in drug-dependent patients compared with what has been described in methadone maintenance patients 9, 10 (MMPs). A number of studies on drug-addicted patients with methadone treatment have shown cognitive impairment and deficits in tasks involved in driving such as visual search, tracking, vigilance, divided attention, and reaction time (see Refs 11,12 for reviews). Studies indicate impairment for MMPs in psychomotor speed, working memory, decision making, and visual orientation. 10, 13 There is no evidence that buprenorphine (up to 8 mg) impairs cognitive performance in drug-dependent patients.
14 Previous data from nonrandomized studies showed that buprenorphine-treated patients perform better in cognitive testing than methadone-treated patients. 15 We tried to replicate these findings in a randomized clinical study.
MATERIALS AND METHODS
The German Ministry of Science (BMBF) is currently funding 4 addiction research networks, including the Bavarian-Saxonian network, Allocating Substance Abuse Treatments to Patient Heterogeneity. 16 One of the projects funded is the study Optimizing Substance Abuse Treatment in Drug Addiction. The major goal of this multicenter study is to improve substitution treatment of opioid-dependent patients by testing different psychotherapeutic approaches in 2 groups of patients randomly allocated either to buprenorphine or methadone treatment for 6 months. 17 Dose adjustments are performed at the physician's discretion. At the center in Munich, cognitive function was measured at baseline and under steady-state conditions after 8 to 10 weeks. The study was approved by the local ethics committee of the University of Munich.
Subjects
In this study, we enrolled 62 patients who met the International Statistical Classification of Diseases, Tenth Revision and Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition criteria for opioid dependence. They were randomly assigned to buprenorphine (BUP) or methadone treatment (MMP). There was no significant difference in age, sex, duration of opioid dependence, or education between the MMP and BUP groups. Patients were excluded if they had a disabling physical disorder or organic brain disorder. All patients were free of withdrawal symptoms when tested, had a driver's license (valid or withdrawn), or were experienced drivers. All subjects participated voluntarily in the study and gave informed consent. A description of the study patient population is presented in Table 1 .
Psychomotor, Cognitive, and Visual Perception Tests
At baseline, during the first week of treatment, patients were examined using a short neuropsychological test battery (all tests together lasting approximately 15 minutes) to exclude possible differences in attention, memory, or word production between both groups. The following tests were conducted:
d2 Test. The d2 test is a widely used attention test. 18 The participant has to mark all ''d'' with 2 lines in a series including a lot of d, p, or q with 1, 2, or 3 lines. The test is to be performed during a fixed amount of time. The final score is the percentage of correct items marked. Digit span test (working memory). This task is the paperpencil version of the Digit span test, a subtest of the Hamburg-Wechsler Intelligence Test, Revised Version of 1991. 19 In response to randomly selected digits (1 -9) spoken by the test assistant, participants have to repeat the digits, first in the same order, then backward. The digit span test provides evaluation of the patient's working memory. The final score for evaluation is the number of correct repeated digits. Regensburger-Wortflüssigkeits test. This test allows measurement of formal and semantic word fluency and cognitive flexibility (shifting). 20 Such tasks are very common in neurocognitive testing. In this test, the participant has to produce as much words as possible in a defined time following different rules, for example, to produce as much words as possible beginning with a certain letter or from a certain category. A reduced word fluency was found in different groups of psychiatric and neurological patients. 21 -23 After 8 to 10 weeks of steady-state conditions of maintenance therapy, patients were tested with a large neuropsychological test battery (lasting approximately 2 hours). Data were collected with the computerized Act & React Test System (ART-90) 24 which has been developed in cooperation with the Austrian Road Safety Board. Various domains such as visual perception, selective attention, vigilance, reactivity, and stress tolerance, which are of relevance for driving fitness, are assessed in different subtests. These tasks were selected as they are part of the driving examinations in Germany according the German Guidelines for Traffic Safety 25 and have been used in previous studies investigating driving fitness. 26, 27 The validity of this method has been confirmed in large samples of both healthy controls and clinical samples. In several driving experiments, the tests have been found to predict driving performance under different traffic situations. 28, 29 The different test batteries on baseline and in steady state were used as the ART-90 tests are not validated for retesting after some weeks because of training effects. Beyond the duration of 2 hours of cognitive testing at the beginning of the study (together with the medical examinations and interviews) would have required much attention and effort from this type of patient.
The test battery comprised the following domains: visual perception was assessed with the tachistoscope test. Typical traffic situations are presented on 15 color slides each for 0.75 seconds. After each slide, the patient has to answer 3 multiple-choice questions by pointing with an electronic pen on the screen. The number of correct and wrong answers are registered. Divided attention was measured with peripheral vision test (PVT) with tracking task. This test requires the subject to perform a tracking task on a screen in front of him while monitoring a light pattern that randomly moves from the right or left visual periphery to the center of the visual field. Reaction time and tracking results are critical variables in this test. In the attention test (Q1), patients have to watch simple figures in a timedependent manner for a period of 7 minutes. Subjects are asked to press 1 of 2 keys for either ''identical figure'' or ''different figure.'' Reactivity and stress tolerance were examined with the reactive stress tolerance test (RST3). Color, tone, and light stimuli are presented in 3 test phases with 180 signals each. In the first trial, stimuli are presented with an interstimulus interval of 1.58 seconds. The second phase (fast phase) has an interstimulus interval of 0.95 seconds, and in the third phase (moderate phase), stimuli appear every 1.07 seconds. Patients have to press corresponding keys and pedals with hand and feet. In the DR2 (decision and reaction test), the person has to press a button when a defined tone and light signal appear. The final score is based on correct decisions and decision time. Mean level of education: 1 = no degree; 2 = 9 years of education; 3 = 10 years of education; 4 = 13 years of education; 5 = university degree.
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Statistical Analysis
Statistical data analysis was performed using SPSS (Statistical Package for Social Science, version 12.0, SPSS Inc, Chicago, Ill, 2003). Nonparametric tests were conducted because the test scores were not normally distributed. The Mann-Whitney U test was used to determine between-group differences, and Spearman correlation was used to determine the relation between neurocognitive test results and age, education, duration of opioid dependence, and dosage of medication. Cutoff level of 0.05 was used for statistical significance and 0.10 for trend. There was no correction for multiple comparisons because of the relative small number of variables.
RESULTS
From the 62 patients included, 16 patients (26%) dropped out of maintenance therapy before the neuropsychological testing at steady state in treatment weeks 8 to 10 (7 of these patients under methadone and 9 under buprenorphine). Thirty-nine (85%) of 46 tested patients in weeks 8 to 10 were using cannabis, benzodiazepines, or opioids. Only 7 patients showed a negative urine testing for drugs. At baseline, there were no significant differences in the d2 attention test, in the digit span test, and the world fluency test between both groups (Table 2) .
Testing in treatment weeks 8 to 10 compared both groups on each test score of the 5 computerized tests ( Table 3 ). The patients under buprenorphine treatment showed a better performance in 2 tests. On the PVT, a tendency of a group difference was found in 1 item of the test. Patients treated with buprenorphine showed a better psychomotor performance on the tracking task; no betweengroup differences were found on reaction time on this test. With respect to the tachistoscope test, the Q1, and the RST3, no significant differences between groups were found. On the DR2, buprenorphine-treated patients had significantly less false reactions than the methadone-treated patients at the same reaction time.
We also conducted a correlation analysis to examine the relationship between psychomotor test performance and age, education level, and duration of opioid dependence. No association was found between psychomotor test results and education. We did find, however, a significant but low correlation between age and reaction time in the PVT (r = À0.269, P = 0.041) and correct answers on Q1 (r = À0.269, P = 0.041). Similarly, we did find a significant but low correlation between duration of opioid dependence and correct answers in Q1 (r = À0.222, P = 0.018) and false decisions in DR2 (r = 0.342, P = 0.009). There was no association between dosage of methadone and test performance. We found a significant medium association between dosage of buprenorphine and the RST3 (phase 2) (r = 0.526, P = 0.011) and false decisions in the DR2 (r = 0.517, P = 0.008).
DISCUSSION
The clinical results from this experimental study indicate a tendency of better psychomotor performance of buprenorphine-treated patients compared with MMPs in some of the tested domains, but we found no clear significant differences in most of the items. There are some limitations to this study basically due to the small number of patients tested and the high number of positive testing for cannabis or other substances in both groups. In a previous nonrandomized study, BUP patients, compared with MMPs, showed better results especially in the most sensitive tests for psychomotor performance under stress conditions (RST3) and monotony (Q1). 15 In this study, patients were better in tracking tasks (PVT) and DR2. Still, these findings are partially in line with some other previous studies. Whereas Lenné et al, 30 using a driving simulator in patients with 31 reported results in BUP patients and MMPs using the same test battery as in our study. Although both groups did not differ significantly in comparison to healthy controls in the majority of the ART-90 standard tests with the exception of Q1 and the DR2 test, BUP patients performed better especially in the Q1 subtest. Both studies were nonrandomized.
Although an individual's driving ability cannot be discussed only with respect to cognitive functioning, other variables such as comorbid psychiatric or personality disorder, driving experience, and psychosocial integration are also of relevance, among others. Still, cognitive function is of great relevance in this respect. The results of the study may indicate a less severe effect on cognitive-motor performance of a mixed agonist/antagonist opioid compared with a full agonist such as methadone. 9 -11 These findings may also be of relevance with respect to social function, rehabilitation, and psychotherapy of patients and safety issues.
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